and eosin staining as well as immunostaining. BrdU (10 mg/kg; B5002;
Sigma-Aldrich) was injected subcutaneously in Utx+/+and UtxF/F Atoh1-Cre SmoM2 mice at P13. Mice were
harvested 24 hours later, and their brains were fixed in 4% PFA at 4 °C
overnight. The fixed brains were subject to subsequent double immunofluorescent
staining of BrdU and HuC/D. For systematic CD3 T cell quantification, every
5th section throughout the tumor tissue was used to determine the
total number of T cells in each tumor sample (n=5 for
Utx+/+ tumors and n=3 for
UtxF/F tumors). The antibodies used were
against Ki67 (eBioscience), CD3 (ab16669, Abcam), UTX (33510, Cell Signaling
Technology), BrdU (G3G4, DHSB), HuC/D (ab184267, Abcam), microtubule-associated
protein 2 (MAP2, M9942, Sigma), NEUROD2 (ab104430, Abcam), NeuN (ABN78,
Millipore) and beta III Tubulin (TUBB3, ab78078, Abcam). Bright-field images
were acquired using a Hamamatsu Nanozoomer 2.0 HT whole slide scanner at the
University of Texas Southwestern Medical Center Whole Brain Microscopy Facility.
Fluorescent images were acquired by a confocal system (Zeiss LSM710), and three
images were taken per tumor at 200x magnification and processed using
ImageJ.